Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121665 | 0.85 | KMT2A (0.58) | RAB9AKMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL27578671 | 0.81 | RAB9A (0.70) | RAB9AKMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4122854 | 0.80 | KMT2A (0.56) | RAB9AKMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL4118526 | 0.80 | MAPT (0.66) | RAB9AKMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL4121525 | 0.79 | CNR1 (0.57) | KMT2ASMN1; SMN2LMNAMEN1MAPT | |
| SCHEMBL4124271 | 0.79 | RAB9A (0.64) | RAB9AKMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL27578667 | 0.79 | RAB9A (0.74) | RAB9AKMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4118387 | 0.78 | MAPT (0.60) | RAB9AKMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4112485 | 0.78 | KDM4E (0.70) | RAB9AKMT2ASMN1; SMN2LMNANPC1 | |
| SCHEMBL27578720 | 0.78 | L3MBTL1 (0.77) | RAB9AKMT2ASMN1; SMN2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885KMT2A 2807/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.